David Ilson
大卫·伊尔森
MD, PhD
Attending Physician, Gastrointestinal Oncology Service; Member, MSKCC胃肠肿瘤服务主任医师；纪念斯隆凯特琳癌症中心成员
👥Biography 个人简介
Dr. David Ilson is one of the world's foremost esophageal cancer oncologists at MSKCC. With over three decades of experience, he has defined preoperative chemoradiation standards, developed novel chemotherapy regimens, and authored foundational clinical trials shaping esophageal cancer management globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Preoperative Chemoradiation Standards
Developed and refined neoadjuvant chemoradiation protocols for resectable esophageal cancer, improving pathologic complete response rates and contributing to current CROSS-based clinical standards.
Novel Chemotherapy Regimens
Introduced and validated irinotecan-cisplatin and paclitaxel-based regimens for advanced esophageal cancer, expanding the therapeutic armamentarium and informing standard-of-care chemotherapy backbones.
Representative Works 代表性著作
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer
Journal of Clinical Oncology (1999)
Established irinotecan-cisplatin as an effective doublet for advanced esophageal cancer, offering an alternative to cisplatin-fluorouracil and informing subsequent combination strategies.
Esophageal cancer
New England Journal of Medicine (2008)
Comprehensive review defining epidemiology, staging, multimodality treatment, and emerging targeted therapy approaches for esophageal cancer, widely cited as a reference for clinicians.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 大卫·伊尔森 的研究动态
Follow David Ilson's research updates
留下邮箱，当我们发布与 David Ilson（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment